ReviewOpen biology2025
Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma.
Review in Open biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Typically, unchecked pancreatic cell proliferation results in the development of pancreatic cancer, which has the potential to spread to other bodily organs. About 90% of instances of pancreatic cancer are pancreatic adenocarcinomas. About 10-20% of pancreatic carcinomas are resectable and potentially curable, and the 5-year survival rate is only 4%; as a result, the majority of pancreatic cancer treatments are palliative in nature. Surgical resection is the only curative treatment; however, because of late diagnosis, the majority of patients appear at an advanced stage, and only a small percentage (10-20%) of them are candidates for surgery. Due to pancreatic cancer's strong resistance to practically all chemotherapeutic drugs and conventional radiotherapies, conventional radiation and chemotherapies have little effectiveness in extending patients' overall life. A lot of scientific studies, however, frequently use the metaphorical term 'double-edged sword' to indicate how autophagy plays a different function in cancer. The use of autophagy inhibitors is thought to be advantageous in combining antineoplastic drugs to improve the sensitivity of cancer cells to therapeutic compounds that activate autophagy. In this review, we aim to look into autophagy along with searching for the most effective strategy in order to treat pancreatic adenocarcinoma with the least drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.